Lipigon is happy to announce 3 new major partners investing in the company. Umeå based Fort Knox Förvaltning AB (Owner of Balticgruppen) and Partnerinvest Övre Norrland AB together with Antaros Medical AB in Gothenburg have entered as new shareholders. The investments allow for Lipigon to expand within present programs and to evaluate novel targets.
“We are very pleased to announce 3 new partners as stakeholders in Lipigon. With these new investors, we are getting the necessary long-term commitment that we need to grow and build a sustainable research based company. Fort Knox and Partnerinvest are experienced life science investors with the necessary financial means to support present and future capital needs. We are also bringing an excellent collaboration partner on board that compliment us very well. Antaros Medical is perfectly situated to support us when our programs reach clinical phases through their expertise in medical imaging and drug development.” says co-founder and CEO Stefan K Nilsson. “There is a lot of excitement in the company. We have a very interesting year coming up and high expectations for the future.”
The excitement is shared by the new investors;
“We feel proud to welcome Lipigon to the Fort Knox family, and look forward to be a part of Lipigon’s journey” said Markus Olsson, CEO, Fort Knox.
Investment manager at Partnerinvest Mattias Eriksson fills in;
“Lipigon has leading knowledge within the area of metabolism and we see a great potential in the company. We are also very pleased to do this investment together with Fort Knox and Antaros.” says Eriksson.
Antaros Medical´s CEO, Johannes Hulthe, points out the synergy effects;
“We believe there are several synergy effects between the strong metabolic research focus in Lipigon and the experience Antaros Medical brings in terms of drug development as well as imaging methodologies to explore early efficacy signals in humans. We are proud to be part of the exciting journey that lies ahead”, says Hulthe.
Lipigon is a spin out from Umeå University in Sweden. The company was founded by leading scientists in the field of cellular lipid transport. Lipigon is currently focusing on the discovery and development of novel treatments for dyslipidemia and metabolic diseases. Learn more at: www.lipigon.se
For further information, please contact: Stefan K. Nilsson, CEO, Lipigon Pharmaceuticals e-mail: email@example.com Tel: +46 70 578 176
Partnerinvest invests in potential growth companies in Norrbotten and Västerbotten. Partnerinvest started the business in 2010 by initiative of ALMI Invest AB and Norrlandsfonden. 50 % of the capital in the first fund (179 Mkr) came from the EU structural funds and the other 50% from the County Administrative Boards of Norrbotten and Västerbotten, Region Västerbotten and the owners ALMI Invest AB and Norrlandsfonden. Late in 2015 the second fund (160Mkr) became active. With the exception for the County Administrative Board of Västerbotten, the second fund has the same financers as the first fund. Learn more at: www.partnerinvestnorr.se.
For further information, please contact: Mattias Eriksson, Investment Manager at Partnerinvest Övre Norrland AB, firstname.lastname@example.org
About Fort Knox
Fort Knox is not only a company with a focus on asset management. We are an entrepreneurial company that invests in companies with ideas that can grow. Fort Knox is a company that believes in Umeå.
About Antaros Medical
Antaros Medical is an R&D company within the Life Science area. The company is pioneering new frontiers in innovative PET and MR imaging methods, leading to improved, evidence-based decision making in clinical drug development. The company is specialized in cardio-metabolic diseases and oncology. Antaros Medical has a global network of customer including both big and small drug developing companies. Learn more at: www.antarosmedical.com
For further information, please contact: Johannes Hulthe, CEO, email@example.com